Literature DB >> 9353650

The usefulness of average cost-effective ratios.

E M Laska1, M Meisner, C Siegel.   

Abstract

We demonstrate that average cost-effectiveness ratios (CERs) play an important role in the evaluation of the cost-effectiveness of treatments. Criticisms of the usefulness of CERs derive mostly from the context of resource allocation under a constrained budget in which some decisions are based on incremental CERs. However, we show that in many cases, these decision rules are equivalent to decision rules on CERs. This follows for mutually exclusive treatments first, because a treatment is eliminated by extended dominance if and only if there is a mixed treatment with a smaller CER, where the mixing parameter lies in a certain interval. Second, after elimination of treatments by dominance and by extended dominance, resources can be allocated in order of increasing CERs. Moreover, the CER is a parameter that characterizes clinical and economical properties of a treatment independent of its comparators.

Mesh:

Year:  1997        PMID: 9353650     DOI: 10.1002/(sici)1099-1050(199709)6:5<497::aid-hec298>3.0.co;2-v

Source DB:  PubMed          Journal:  Health Econ        ISSN: 1057-9230            Impact factor:   3.046


  5 in total

1.  Cost-effectiveness analysis: a proposal of new reporting standards in statistical analysis.

Authors:  Heejung Bang; Hongwei Zhao
Journal:  J Biopharm Stat       Date:  2014       Impact factor: 1.051

2.  Cost-effectiveness of bupropion, nortriptyline, and psychological intervention in smoking cessation.

Authors:  Sharon M Hall; James M Lightwood; Gary L Humfleet; Alan Bostrom; Victor I Reus; Ricardo Muñoz
Journal:  J Behav Health Serv Res       Date:  2005 Oct-Dec       Impact factor: 1.505

3.  Average cost-effectiveness ratio with censored data.

Authors:  Heejung Bang; Hongwei Zhao
Journal:  J Biopharm Stat       Date:  2012       Impact factor: 1.051

4.  Median-based incremental cost-effectiveness ratios with censored data.

Authors:  Heejung Bang; Hongwei Zhao
Journal:  J Biopharm Stat       Date:  2015-05-26       Impact factor: 1.051

5.  Impact of assumptions on future costs, disutility and mortality in cost-effectiveness analysis; a model exploration.

Authors:  Amir-Houshang Omidvari; Iris Lansdorp-Vogelaar; Harry J de Koning; Reinier G S Meester
Journal:  PLoS One       Date:  2021-07-12       Impact factor: 3.752

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.